Nektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics

Overview
Date Founded

1998

Headquarters

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158

Type of Company

Public

Employees (Worldwide)

723

Industries

Pharmaceuticals
Biotechnology
Hospitals & Patient Services

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Contact Data
Trying to get in touch with decision makers at Nektar Therapeutics? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Senior Vice President, Chief Operating Officer & Chief Financial Officer

Chief Financial Officer

Secretary, Senior Vice President & General Counsel

Senior Vice President & Chief Commercial Officer

Senior Vice President, Finance & Chief Accounting Officer

Chief Research & Development Officer

Senior Vice President & Head of Development

Senior Vice President, Clinical Development & Head of Nektar's Immunology Program

Senior Vice President, Strategy & Corporate Affairs

Board of Directors

Co-Founder at Biota Technology, Inc.

Chief Medical Officer & Executive Vice President at Intuitive Surgical, Inc.

Member & Supervisory Board at MorphoSys AG

Founder at Numenor Ventures LLC

Executive Vice President & Chief Commercial Officer at BioMarin Pharmaceutical, Inc.

President & Chief Executive Officer at Nektar Therapeutics

Co-Founder at Incyte Corp.

Paths to Nektar Therapeutics
Potential Connections via
Relationship Science
You
Nektar Therapeutics
Owners & Shareholders
Details Hidden

Maverick Capital’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that it believes offer the highest returns relative to risk, regardless of index weightings, market capitalization or style orientations. Their research is augmented by a top-down view of individual industries, as well as the efforts of their quantitative research team. While fundamentals still drive security selection, the quantitative research effort plays an important role in Maverick’s portfolio construction, security selection and risk management. The firm’s investment team is organized into six industry sector teams: Consumer, Financials, Healthcare, Industrials, Media & Telecom and Technology. The industry sector teams are supported by two discipline research teams: private investments and quantitative. The firm’s founder – Lee S. Ainslie III – has ultimate responsibility for all portfolio decisions for Maverick Funds and related Separate Account Clients.

Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, the firm may occasionally invest in other sectors if more attractive opportunities are identified. Camber Capital Management employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation.

Recent Transactions
Details Hidden

Nektar Therapeutics issued USD Common Stock

Details Hidden

Nektar Therapeutics, Aerogen, Inc. purchase Aerogen Ltd.

Details Hidden

Nektar Therapeutics issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Accountant

Advised onNektar Therapeutics purchases Shearwater Corp.

Underwriter

Advised onNektar Therapeutics issued USD Common Stock

Underwriter

Advised onNektar Therapeutics issued USD Common Stock

Legal Advisor

Advised onNektar Therapeutics issued USD Common Stock

Legal Advisor

Advised onNektar Therapeutics issued USD Common Stock

Head, Healthcare Investment Banking

Advised onNektar Therapeutics issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Advisor

Chief Technical Operations Officer at Amunix, Inc.

Legal Advisor

Partner at Cadwalader, Wickersham & Taft LLP

Clients

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Key Stats and Financials As of 2019
Market Capitalization
$2.97B
Total Enterprise Value
$2.9B
Earnings Per Share
$-2.52
Revenue
$115M
EBITDAMargin
-374.32%
Enterprise Value / Sales
25.33x
TEVNet Income
-6.59x
Debt TEV
0.16x
Total Debt
$451M
Total Equity
$1.41B
EBITDA
$-429M
Net Profit
$-441M
Three Year Compounded Annual Growth Rate Of Revenue
-11.51%
Non-Profit Donations & Grants
$5,000 - $10K
2014
$500 - $999
2014
$5,000 - $10K
2014
Political Donations
$6,500
2012
Investments
Details Hidden

Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA.

Suppliers
ImaginAb, Inc. Medical Support Services | Inglewood, CA

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Kilroy Realty Corporation Trusts & Funds | Los Angeles, CA

Kilroy Realty corp KRC has successfully operated in West Coast commercial real estate markets for more than six decades. We have built deep experience in the region serving its many dynamic economic centers across multiple business cycles and operating environments. Today, we operate a portfolio of high quality commercial properties totaling more than 12.5 million square feet that span top coastal market locations from Seattle to San Diego. We serve a broadly diversified roster of industries, including many of the region’s leading firms in technology, telecommunications, engineering, entertainment, healthcare, biotechnology, and professional services. A fully integrated real estate enterprise Our decades of experience have taught us the wisdom of mastering all the disciplines of our profession. KRC's core management capabilities encompass all aspects of real estate, including property and land acquisition, financing and property development, construction management, leasing and property operations, and long-term strategic portfolio development. This integrated approach to real estate ownership produces efficiencies throughout our enterprise. It also creates a sound base from which to navigate challenging conditions and capitalize on nascent opportunities that are both part of a normal real estate business cycle. In 1997, we became a publicly traded real estate investment trust. Our common stock trades on the New York Stock Exchange and, in 2001, was added to the S&P MidCap 400 Index. In 2010, our publicly traded debt securities were rated investment grade by Moody’s and Standard and Poor’s. Public ownership and investment grade debt ratings both enhance our access to a variety of financing sources at attractive rates, and supports our ability to fund growth while also maintaining a strong and flexible capital structure. A disciplined business strategy Operating in one of the most dynamic economic regions of the world has shaped our business strategy at KRC. Our primary goal is to deliver a steady stream of high quality, adaptable and productive work environments for the wide range of industries attracted to the vibrant economic centers dotting the west coast of the United States. We are opportunistic and disciplined in our approach to growth. We seek to capitalize on inflection points in a real estate cycle to add quality assets to our portfolio at substantial discounts to long-term value, through either acquisition or development. Since early 2010, we have significantly increased our asset base via acquisition, purchasing a variety of properties that meet our strict standards for quality, location, amenities and long-term appreciation potential, at what we consider to be at or near cyclically low prices. Our acquisition strategy targets two distinct opportunities: best-in-class properties that are unique and irreplaceable within their specific markets and selling at or below replacement value; and well-located, fundamentally sound properties that represent opportunities to substantially increase value over time via disciplined investment and/or improved property management and marketing. In today’s real estate environment, we continue to see and evaluate both types of acquisition opportunities. We also manage our portfolio of office properties to continually enhance its overall value. We regularly sell mature assets and recycle the capital into higher value properties, upgrading the quality of our portfolio while maintaining a healthy balance sheet and enhancing the potential returns we can generate for our shareholders. Strong and broad-based development experience When market conditions support it, we have a bias toward development, preferring to control the location, design and amenities of the properties we add to our portfolio. Such control can often produce a more appealing and functional property for our tenants and a better outcome for our shareholders. We maintain an active, multi-year development program, focusing on economically dynamic locations where anticipated long-term demand is strong, supply is habitually limited and barriers to entry are formidable. Typically this means the top coastal submarkets that offer both a vibrant economic backdrop for businesses and a unique quality of life for their employees.

Pharmicell Co., Ltd. Pharmaceuticals | Seoul, South Korea

Pharmicell Co., Ltd. is engaged in the development of stem cell based pharmaceuticals and technologies. It operates through the Bio and Chemical Business Divisions. The Bio division provides cosmetics, cell for researches, medical testing equipment, and others. The Chemical division offers nucleoside, agricultural pesticides, fire retardant materials, and others. The company was founded on August 20, 1968 and is headquartered in Seoul, South Korea.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, Canada

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Nektar Therapeutics. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Nektar Therapeutics's profile does not indicate a business or promotional relationship of any kind between RelSci and Nektar Therapeutics.